strong-ipo-demand-for-3sbio-but-shares-fall-on-debut

Strong IPO demand for 3SBio, but shares fall on debut

The decline comes after the Chinese bio-pharmaceutical firm prices its IPO above the range. Fellow Nasdaq newcomer JA Solar trades up.
Chinaûbased 3SBio IncÆs initial public offering in the US has met with overwhelming investor support, allowing the price to be fixed 14.3% above the top end of the indicated price range.

The bio-pharmaceutical company, which sells its products across China as well as to selected developing countries, raised $123.2 million ahead of its Nasdaq trading debut yesterday, tapping into the strong demand for healthcare investments by US funds in particular.

UBS was sole bookrunner for the offering, while CIBC World Markets and Pacific Growth Equities were also part of the underwriting syndicate.

3SBio focuses on genetically-engineered, protein-based products targeted at the areas of nephrology, oncology, supportive cancer care, inflammation and infectious diseases. It has a...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222